Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21 by El-Khatib, Mona et al.
RESEARCH Open Access
Cell death by the quinoxaline dioxide DCQ in
human colon cancer cells is enhanced under
hypoxia and is independent of p53 and p21
Mona El-Khatib
1, Fady Geara




Introduction: We have shown that the radio sensitizer DCQ enhances sensitivity of HCT116 human colon cancer
cells to hypoxia. However, it is not known whether the p53 or p21 genes influence cellular response to DCQ. In
this study, we used HCT116 that are either wildtype for p53 and p21, null for p53 or null for p21 to understand the
role of these genes in DCQ toxicity.
Methods: HCT116 cells were exposed to DCQ and incubated under normoxia or hypoxia and the viability, colony
forming ability, DNA damage and apoptotic responses of these cells was determined, in addition to the
modulation of HIF-1a and of p53, p21, caspase-2, and of the ataxia telangiectasia mutated (ATM) target PIDD-C.
Results: DCQ decreased colony forming ability and viability of all HCT116 cells to a greater extent under hypoxia
than normoxia and the p21
-/-cell line was most sensitive. Cells had different HIF-1a responses to hypoxia and/or
drug treatment. In p53
+/+, DCQ significantly inhibited the hypoxia-induced increases in HIF-1a protein, in contrast
to the absence of a significant HIF-1a increase or modulation by DCQ in p21
-/- cells. In p53
-/- cells, 10 μM DCQ
significantly reduced HIF-1a expression, especially under hypoxia, despite the constitutive expression of this protein
in control cells. Higher DCQ doses induced PreG1-phase increase and apoptosis, however, lower doses caused
mitotic catastrophe. In p53
+/+ cells, apoptosis correlated with the increased expression of the pro-apoptotic
caspase-2 and inhibition of the pro-survival protein PIDD-C. Exposure of p53
+/+ cells to DCQ induced single strand
breaks and triggered the activation of the nuclear kinase ATM by phosphorylation at Ser-1981 in all cell cycle
phases. On the other hand, no drug toxicity to normal FHs74 Int human intestinal cell line was observed.
Conclusions: Collectively, our findings indicate that DCQ reduces the colony survival of HCT116 and induces
apoptosis even in cells that are null for p53 or p21, which makes it a molecule of clinical significance, since many
resistant colon tumors harbor mutations in p53.
Introduction
Hypoxia develops due to the inadequate vascularization
during early tumor development and is believed to be
the major factor causing tumor resistance to radiother-
apy and chemotherapy [1]. Numerous gene products,
which are activated under hypoxia, are involved in
tumor metastasis and neoangiogenesis. On the other
hand, hypoxic cells contain high levels of bioreductive
enzymes and thus represent a therapeutic target if
directly targeted by hypoxia-activated drugs [2].
Quinoxaline 1,4-dioxides (QdNOs) are the prototype for
current heterocyclic N-oxide anticancer agents such as 3-
amino-1,2,4-benzotriazine 1,4-dioxide (Tirapazamine-
TPZ). Among four QdNOs tested, we found DCQ (2-
benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide) to
be the most effective hypoxic cytotoxin [3-6]. Although
DCQ is not a benzotriazine 1,4-dioxide like TPZ, it resem-
bles TPZ in that these two compounds are electron-poor
by virtue of the formal positive charges held by the two
nitrogens of the N-O functions in each of them. In fact,
DCQ is believed to be more electron-poor than TPZ
because it has more electron attracting substituents: the 2-
benzoyl group and the 6,7-dichloro substituents. These
substituents render the quinoxaline 1,4-dioxide moiety
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and in analogy with the mechanism of action of TPZ [7],
the radical that results from addition of an electron to C2
of DCQ is more stable, by resonance, and therefore longer
lasting and more damaging to DNA than the radical
resulting from the addition of an electron to TPZ.
DCQ was shown by our group to reduce cell growth
in T-84 human colon cancer cells, and in SP-1 keratino-
cyte cell line, under both normoxia and hypoxia; how-
ever, drug toxicity was greater in cells exposed to
hypoxia [3]. DCQ was found to decrease the expression
levels of the hypoxia inducible factor (HIF-1a)m R N A
and protein in the human colon carcinoma cell line
T-84, and in EMT6 mouse mammary carcinoma cells
and Lewis Lung Carcinoma (LLC) cells [4,8]. We also
showed that DCQ inhibited cell proliferation and
induced apoptosis in colon T-84 cancer cell lines under
normoxia via the inhibition of the extracellular signal
regulated kinase (ERK) phosphorylation and reduction
in Bcl-2a protein [9]. While in adult T-cell leukemia,
DCQ reduced cell proliferation by decreasing Tumor
Growth Factor (TGF)-a, a key mediator of growth sti-
mulation with mitogenic effects, and by increasing the
mRNA and protein expression levels of the proapoptotic
TGF-b1 [6]. When studying the efficacy of DCQ as a
normoxic radiosensitizer, clonogenic survival assays in
LLC and EMT6 cell lines revealed an enhancement of
the radiation effect [8,10]. In vivo, DCQ in combination
with radiation delayed the growth of LLC tumors
injected in C57BL6 mice, reduced the mean tumor
volume by 80% and inhibited tumor angiogenesis [8]. In
a recent study, DCQ was found to induce single strand
breaks (SSB) in DNA of DLD-1 human colon cancer
cells, and both SSB and double strand breaks (DSB) in
EMT6 cells [5,11].
DNA damage, in particular DSBs, imposes a critical
threat to the survival of cells if left unrepaired [12]. At
very early stages of the DNA damage response, cells acti-
vate the DNA damage checkpoint ATM, a member of
phosphoinositide 3 kinase-related kinase (PIKK) which is
involved in DNA repair [13]. ATM activation, in turn,
leads to the phosphorylation of p53, thereby blocking its
interactions with MDM2, and causing p53 stabilization.
This, in turn, stimulates the expression of the cyclin-
dependent kinase (CDKs) inhibitor p21. Through its
negative effects on various CDKs, p21 inhibits G1/S and
G2/M transitions. Thus, increased p53 levels due to the
ATM-p53-p21 pathway activation lead to cell-cycle
arrest, repair, and cell death [14]. Tumor cells that harbor
defective p53 have no such checkpoint mechanisms,
which favor their clonal outgrowth. The activation of
ATM also leads to the activation of PIDD (p53-induced
protein with a death domain), an important target gene
in a signaling pathway initiated by p53. The tumor
suppressor protein p53 has been also found to be acti-
vated in response to cellular stress, chemotherapeutic
drugs and hypoxia [15].
If DNA damage is severe, the initiator caspase-2 is
activated. This caspase possesses a caspase recruitment
domain (CARD) that allows it to interact with PIDD.
Caspase-2 activation can be initiated in the PIDDosome,
the assembly of which is mediated by PIDD autoproces-
sing to generate a PIDD-CC fragment necessary for cas-
pase-2 activation [16]. A recent study has demonstrated
that p53 controls the expression of PIDD that, in turns
recruits procaspase-2 by interaction with its prodomain
[16]. The resulting complex activates caspase-2 without
interdomain cleavage of caspase-2 [16]. The activation
of caspase-2 within the PIDDosome complex results in
cytochrome c release and the activation of other cas-
pases which are involved in the mitochondria-mediated
apoptotic pathway [17]. Caspase-2 activation has been
shown to be involved in metaphase-associated mitotic
catastrophe [17], which is characterized by multinu-
cleated giant cells with nuclear envelopes forming
around individual clusters of mis-segregated uncon-
densed chromosomes [17].
This project aimed to investigate the cytotoxicity of
DCQ in HCT116 human colorectal cancer cell lines that
are either wildtype for p53 and p21, null for p53, or null
for p21 to determine the role of these genes in cellular
response to DCQ. Since DCQ has been previously
shown to exhibit enhanced toxicity in hypoxic tumor
cells, its activity was determined in HCT116 cells
exposed to either normoxia or hypoxia. We also investi-
gated if DCQ causes apoptosis, induces SSB and acti-




Propidium iodide (PI), YOYO-1 dye, fluorescein isothio-
cyanate (FITC) goat anti-mouse IgG (H+L), and
5-(and-6)-chloromethyl-2’,7’-dichlordihydrofluorescein
diacetate, acetyl ester (CM-H2DCFDA) were purchased
from Molecular Probes (Eugene, Oregon, US). RNase A,
and dimethylsulfoxide (DMSO) were obtained from
Sigma Chemical Company (St. Louis, Missouri, US).
Protease Inhibitor was from Roche Applied Science
(Penzberg, Germany). DCQ was synthesized from 5,6-
dichlorobenzofurazan oxide and dibenzoylmethane by
the Beirut Reaction [18].
Cell culture and treatments
FHs74Int normal human intestinal cells were cultured in
Hybri-Care medium supplemented with 30 ng/ml epi-
dermal growth factor. HCT116 (p53
+/+)h u m a nc o l o n
cancer cells were maintained in RPMI 1640 with 25
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-/-)a n d
HCT116 (p21
-/-) cells were grown in Dulbecco’sM o d i -
fied Eagle Medium (DMEM) supplemented with sodium
pyruvate and 4500 mg/l glucose. All media were supple-
mented with 1% Penicillin-Streptomycin (100 U/ml) and
10% heat-inactivated FBS. All cells were obtained from
ATCC and maintained in a humidified atmosphere of
5% CO2 and 95% air. 10 mg of DCQ was dissolved in
1 ml of DMSO and stored in a brown eppendorf at 4°C
and then diluted in media to attain the drug concentra-
tions of up to 10 μM. For hypoxia exposure, cells were
placed in a tightly sealed anaerobic gas chamber, Bac-
tron III (SHEL LAB, UK) at 37°C and oxygen level <
2%. The desired oxygen level was monitored by an
Ohmeda Oxymeter (Datex-Ohmeda, Louisville CO,
USA) and maintained by pumping a gas mixture com-
posed of 1% O2,5 %C O 2,a n d9 4 %N 2.A f t e r6h ro f
hypoxia exposure, cells were replated with drug-free
media and incubated under normal oxygen for clono-
genic survival assays.
Viability and clonogenic survival
For viability assays, HCT116 or FHs74Int (1.2 × 10
5
cells/ml) were cultured in 96-well plates and treated
with drugs 24 hrs after plating. Antineoplastic effects
were studied 6 hrs or 24 hrs after treatment by the non-
radioactive cell proliferation kit (Promega Corporation,
Madison, USA), an MTT-based method which measures
the ability of metabolically active cells to convert tetra-
zolium salt into a formazan product and its absorbance
is recorded at 570 nm [19]. For clonogenic survival stu-
dies, cells were treated with DCQ for 12 hr under nor-
moxia or hypoxia. Then they were trypsinized, replated
at low densities (300-5000 cells) in T-25 flasks, and left
for 8-14 days in the incubator. Subsequently, cells were
washed with PBS, and stained with 1 ml of aqueous
0.5% solution of crystal violet. Colonies having more
than 50 cells were counted. The plating efficiency (PE),
defined as the ability of control cells to survive and
grow into colonies, was calculated as: PE = colonies
counted in control/plating density of control. Surviving
fraction (SF) for each treatment was calculated as: SF =
colonies counted/[cells plated × (PE/100)]. The SF value
of each treatment was then plotted.
Flow cytometric analysis
Cells were plated in 60-mm dishes (1.2 × 10
5 cells/ml),
treated with different DCQ concentrations at 50% con-
fluency, and incubated for 6 hrs under either normoxia
or hypoxia, then harvested and fixed in 70% ethanol.
Supernatants containing the dead cells were collected
and attached live cells were harvested by 2× trypsin and
added to the supernatant. Flow cytometry analysis of
Propidium Iodide-stained DNA was done as described
previously [19]. Cell Quest program was used to deter-
mine the percentages of cells in various cell cycle
phases. Pre-G1 cells with DNA content < 2n represent
apoptotic or necrotic cells.
Hoechst staining
Cells were plated in 6-well plates at 1.2 × 10
5 and trea-
ted at 50% confluency with DCQ (2.5 or 5 μM) for
6 hrs under normoxia or hypoxia. The drug was then
removed, and cells were washed with 1× PBS and fixed
using 70% ethanol for 24 hrs. Next day, cells were
placed in wet chambers to prevent dehydration, a stock
of Hoechst stain (1:100) was prepared and 100 μlo ft h e
100× diluted Hoechst stain (from the stock) was added
to each slide and incubated for 10 min. A drop of fluor-
osave (antifade) was added on the slides which were
covered with coverslips and kept in the dark at 4°C.
Annexin V
Cells were collected along with the supernatant and cen-
trifuged at 1500 rpm for 10 min, 4°C. The pellet was
washed with PBS and centrifuged at 1500 rpm for
10 min, 4°C. The pellet was resuspended in 100 μl
Annexin-V-Fluos labeling solution (20 μl annexin
reagent and 20 μlP I( 5 0μg/ml) in 1000 μli n c u b a t i o n
buffer pH 7.4 (10 mM Hepes/NaOH, 140 mM NaCl,
5m MC a C l 2). The samples were incubated for 15 min
at room temperature and 0.4 ml incubation buffer was
added. The cellular fluorescence was then measured by
flow cytometry using a Fluorescence Activated Cell
Sorter (FACS) flow cytometer (Becton Dickinson,
Research Triangle, NC).
Western blot
Cellular protein extracts were prepared and proteins
were quantified as described previously [19]. 50 μgo f
whole cell lysate was separated by SDS-PAGE (12%
gels) and transferred to PVDF membranes (Amersham
Pharmacia Biotech, Buckinghamshire, UK) in cold
transfer buffer at 30 Volts overnight. The membranes
were probed with the primary antibodies: p21 ((C-19)-
G), p53 (DO-1), caspase-2 (all from Santa Cruz, Cali-
fornia), ATM kinase phosphoser1981 antibodies (Che-
micon International, California), PIDD (Alexis
Biochemicals, Playmouth, USA), HIF-1a (Novus Biolo-
gicals, Littleton, USA), followed by horseradish peroxi-
dase-conjugated anti-mouse, anti-rabbit, or anti-goat
IgG-HRP (all from Santa-Cruz, California, US).
GAPDH (Biogenesis, Poole, UK) was used to ensure
equal protein loading. The immunoreactive bands were
visualized on X-ray film with chemiluminescent sub-
strate (Santa-Cruz). To quantify protein bands, densi-
tometry was done using LabWorks 4.0 software. Bands
were quantitated with ImageQuant software and the
El-Khatib et al. Radiation Oncology 2010, 5:107
http://www.ro-journal.com/content/5/1/107
Page 3 of 13Molecular Dynamics Storm 860 System (Molecular
D y n a m i c s ,S u n n y v a l e ,C A ) .
Alkaline comet
T h ea l k a l i n ec o m e ta s s a yu s e di sam o d i f i c a t i o no ft h e
method developed by Singh [20]. This method which
was described by us previously [11] detects the fre-
quency of SSBs and alkaline-labile lesions in DNA.
Images of a minimum of 50 cells per treatment were
analyzed using the CometScore™software. Percentage of
DNA in the tail region, and tail moment (% DNA in tail
×b yt a i ll e n g t h( μm)) were used as parameters to assess
DNA damage.
p-ATM immunocytochemistry
Ser-1981-phosphorylated ATM was detected immunocy-
tochemically by multiparameter cytometry with respect to
the cell cycle phases, using the method developed by
Huang and Darzynkiewicz [21]. Cells were collected by
trypsinization, centrifuged, washed with PBS, and fixed
with ice-cold 70% ethanol for a minimum of 2 hr at -20°
C. Ethanol was discarded by centrifugation at a speed of
10000 rpm for 5 min, and the pellets were washed with
BSA-T-PBS containing 1% BSA and 0.2% Triton X-100
dissolved in PBS. The pellets were blocked in BSA-T-PBS
for 5 min at room temperature. After removal of the 1%
BSA solution by centrifugation, the cells were incubated
with the primary antibody Ser-1981-p-ATM at a dilution
of 1:100 overnight at 4°C. The cells were washed twice
with BSA-T-PBS, and the pellets were then incubated in
the dark with fluorescein isothiocyanate (FITC)-conjugated
secondary anti-mouse antibody (1:30) for 1 hr at room
temperature. BSA-T-PBS (5 ml) was added to the cell
suspension and kept for 2 min before centrifugation at
12000 rpm for 4 min. Finally, the cells were counter-
stained with PI (5 μg/ml) solution containing RNase A
(0.1 mg/ml) for 30 min at room temperature in the dark.
Both the fluorescence of PI and FITC of 10
4 cells/treat-
ment were measured using the FACS cytometer, and ana-
lyzed using Cell Quest.
Results
DCQ decreases colon cancer cell growth to a greater
extent under hypoxia
We have previously shown that DCQ is a hypoxic cyto-
toxic compound that induces apoptosis in several murine
and human cancer cell lines [4,5,8]. This is our first
attempt to understand the role of p53 and p21 in drug
efficacy using colon cancer cells that are wildtype or null
for p53 and p21. Before studying DCQ efficacy under
hypoxia, we determined the sensitivity of the colon can-




-/-) cells were exposed to 1% O2 f o r6 ,1 2o r2 4h r s ,
after which cell viability was determined by the MTT-
based Cell Titer Promega assay (Figure 1A). Although up
to 12 hrs of hypoxia had no effect on viability, 24 hrs
reduced it by 50% in p53
+/+ c e l l sa n db ym o r et h a n8 0 %
in p53
-/- and p21
-/- cells (Figure 1A). Therefore, all
further experiments were conducted by exposing cells to
6 or 12 hrs hypoxia. To determine the antineoplastic
effects of DCQ, cells were treated with 5 or 10 μMD C Q
for 6 hrs and cultured under normoxia or hypoxia. These
doses are in the IC50 range for p53
+/+ cells [5]. As shown
in Figure 1B, DCQ inhibited the viability of all three
HCT116 cell lines in a dose-dependent fashion, and this
inhibition was 2-5 fold higher under hypoxia than nor-
moxia. p21
-/- cells appeared to be more sensitive to DCQ
at 10 μM than the other two cell lines (Figure 1B).
Further studies to confirm the higher drug activity
under the reducing conditions of a hypoxic environment
involved carrying out clonogenic survival assays. Cells
were treated with DCQ at concentrations ranging from
1-20 μM for 6 hrs (data not shown) or 12 hrs, and
exposed to normoxia or hypoxia, after which cells were
re-plated at low density and incubated for 8-14 days.
Colonies having more than 50 cells were counted and
surviving fractions were plotted (Figure 2A). DCQ
decreased the colony forming ability in a dose-
dependent fashion for all three cell lines under both
normoxic and hypoxic conditions; however, the effect
was more pronounced under hypoxia and in p21
-/- cells.
In accordance with the MTT results, the clonogenic sur-
vival experiment indicated p21
-/- as drug sensitive and
p53
+/+ as relatively more resistant.
DCQ modulates HIF-1a protein differently in the three
cell lines
To determine whether differences in drug efficacy was
related to the modulation of HIF-1 a,t h et h r e ec e l l
lines were exposed to DCQ (6 hr incubation with 5 μM
or 10 μM) under normoxia or hypoxia and the expres-
sion of HIF-1a protein was determined (Figure 2B). The
level of HIF-1a in hypoxic tumors is known to increase
to regulate metabolic adaptation to oxygen deprivation
and angiogenesis [22-24]. This renders cancer cells bet-
t e ra b l et os u r v i v ei nt h eh a r s hh y p o x i cc o n d i t i o n s[ 2 5 ] .
Therefore, inhibiting HIF-1a-mediated signaling is
important for enhancing anticancer drug efficacy. Differ-
ences in HIF-1a responses to hypoxia exposure and/or
drug treatment were observed in the three cell lines. In
p53
+/+ cells, the HIF-1a protein levels increased by 3.5
fold when cells were exposed to hypoxia, and this
increase was significantly inhibited by 10 μM DCQ (Fig-
ure 2B). This is in contrast to the observed increase in
HIF-1a in response to 5 μMo r1 0μM DCQ under nor-
moxia in this cell line. In p53
-/- cells, however, HIF-1a
protein was constitutively expressed under normoxia
and hypoxia, yet 10 μM DCQ reduced its expression
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note that hypoxia selects for tumors that are mutant for
p53 [26]. In p21
-/- cell, although DCQ altered the pro-
tein level pattern of HIF-1a, no dose-dependent increase
in HIF-1a was observed (Figure 2B).
Low DCQ doses induce mitotic catastrophe while high
doses cause apoptosis
To determine the mode of cell death induced by DCQ,
we exposed HCT116 cells to low (2.5 μM) or high (5 or
10 μM) concentrations of DCQ under normoxia or
hypoxia and analyzed cells by flow cytometry, Hoechst
staining and Annexin V techniques 6-24 hrs later.
Depending on the severity of DNA damage, cancer cells
have been shown to die by apoptosis, necrosis or mitotic
catastrophe. Recent evidence has shown that low doses
of anticancer drugs, like paclitaxel, induce mitotic cata-
strophe followed by apoptosis [27]. In our system, we
observed signs of mitotic catastrophe only in response
to lower concentrations of DCQ (2.5 μM) for 48 hrs.
Under these treatment conditions, the nuclei of all three
HCT116 cells became significantly larger and some cells
contained several nuclei of unequal sizes, which are
characteristic of mitotic catastrophe (Figure 3A). Mitotic
catastrophe was not observed in cells exposed to higher
concentrations of DCQ (5 or 10 μM) under normoxia
or hypoxia (data not shown). The Pre-G1 increase is
indicative of apoptosis and necrosis as evidenced by the
higher percentage of Annexin-positive apoptotic cells
(Figure 3C). In Figure 3C, quadrant A represents apop-
totic cells, B apoptotic and necrotic cells, C normal cells
and D necrotic cells. The percentage of apoptotic and
necrotic cells increased from 8% and 14% in control
normoxic and hypoxic cells respectively, to 31% and
34% in cells treated with 10 μM DCQ. The apoptotic
response and Pre-G1 phase increase was 2-5 fold higher
under hypoxia than normoxia depending on the cell
line, which was in agreement with the clonogenic and
MTT assay observations (Figures 1 and 2). Again, the
p21
-/- cells showed the greatest increase in the Pre-G1
population (Figure 3B), further confirming the higher
drug sensitivity of this cell line.
There is no dose-response toxicity by DCQ in normal
intestinal cells
To determine if DCQ is an effective anti-tumor drug that
specifically targets cancer cells and spares normal ones,
we investigated the dose-response toxicity of DCQ in




-/-) cell viability after 6, 12, or 24 hrs of exposure to 1% O2. Cells were plated in 96 well plates at 1.2 × 10
5 cells/ml and treated at 50%
confluency. Viability was determined using Cell Titer 96 non-radioactive proliferation assay. (B) Dose-dependent decrease in the viability of cells
exposed to DCQ for 6 hrs and cultured under normoxia or hypoxia. Values are averages ± SD of two independent experiments each done in
triplicates; (*) indicates p < 0.05 (one way ANOVA). ■ Normoxia □ Hypoxia. The experiment was repeated three times each in quadruplicates.
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cells with DCQ concentrations of up to 10 μMf o r6h r s
was followed by measuring LDH release and cell viability
by the MTT-based assay. DCQ was not cytotoxic to the
normal intestinal cells (Figure 4A), and although cell via-
bility was reduced by 1 μM of the drug, it did not seem
to change much with dose increase (Figure 4B).
DCQ induces DNA damage and activates ATM in
p53
+/+ cells
Next we investigated whether DCQ causes cell death in
human colon cancer cells by inducing DNA damage and
activating ATM, as similar effects have been observed in
EMT6 mouse mammary carcinoma cell lines [11]. For
this, we used the p53
+/+ cells as model, since this cell line
harbors functional p53 and DCQ significantly decreased
the induction of HIF-1a by hypoxia in p53
+/+ cells (Figure
2B). Cells were treated with DCQ and exposed to nor-
moxia or hypoxia for 6 hrs after which they were subjected
to the alkaline comet assay for determining SSB formation
and to immunocytochemistry for measuring the extent of
ATM activation (an indication of DSB). The extent of SSB
formation in response to DCQ was evaluated and quanti-
fied using TriTek CometScore, software which calculates
different parameters by assuming that the amount of DNA
at a certain location (or the intensity of the DNA stain) is
proportional to the pixel intensity at that position. Differ-
ent parameters were used to quantify the extent of DNA
damage induced by DCQ including % DNA in comet’s tail
(representing damaged DNA migrated away from
nucleus), and tail moment (% DNA in comet’st a i lm u l t i -
plied by the tail length). Under normoxia, DCQ induced a
significant increase in the level of SSBs (Figures 5A, B),
however, under hypoxia, SSB were augmented by the
Figure 2 DCQ reduces the clonogenic survival of HCT116 cells more so under hypoxia than normoxia. (A) Clonogenic survival of DCQ-
treated cells exposed to normoxic or hypoxic conditions. At 50% confluency, cells were treated for 12 hrs with different DCQ concentrations in
normoxia or hypoxia, after which they were replated at low densities and colonies (more than 50 cells) were stained and counted after 10-14
days in culture. Surviving fractions were calculated as mentioned in “Methods”. (*) indicates p < 0.05 (one way ANOVA). (B) Effect of DCQ on
HIF-1a protein expression. Cells were plated in 100 mm dishes and treated for 6 hrs with DCQ while in normoxia or hypoxia. Whole cell lysates
were immunoblotted for HIF-1a. GAPDH was used to ensure equal loading. Relative densitometry values are presented at the bottom of the
blots. All ratios were normalized to GAPDH and calculated relative to the control cells cultured under oxia. The experiment was repeated three
times each in triplicates.
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increased significantly (p < 0.05) in comparison with that
of untreated cells (Figure 5B).
Upon DNA damage, cell cycle checkpoints are acti-
vated. These DNA repair processes are mediated via two
protein kinase pathways: the ATM through Chk2 and
ATR via Chk1 [28-30]. ATM, a member of the PIKK
family, is mainly activated upon DSB formation by the
autophosphorylation of the Ser-1981 [30]. Our results
indicated that control cells have basal levels of p-ATM
expression which are higher in the G2-M population
due to the critical role of ATM in mitosis. Exposure of
p53
+/+ cells to 5 or 10 μM DCQ triggered the activation
of ATM by its phosphorylation at Serine 1981 in all the
phases of cell cycle and this activation was more pro-
nounced under hypoxia (Figure 5C). Hypoxia alone
increased ATM expression, however, the combination of
DCQ and hypoxia treatment induced higher levels of
p-ATM expression in the G2-M phase in comparison
with control cells (Figure 5C). These results confirm
that DCQ induces DSBs in human colon cancer cells.
DCQ modulates protein expression of downstream
ATM effectors
Upon DNA damage, one of the important transcription
factors activated by ATM through phosphorylation is
Figure 3 DCQ induces mitotic catastrophe and apoptosis in HCT116 cells. (A) Low concentrations of DCQ triggered mitotic catastrophe in
all HCT116 cell lines. Cells were cultured on coverslips and treated at 50% confluency with 2.5 μM DCQ for 48 hrs after which they were fixed
and stained with Hoechst and viewed under a fluorescent microscope using UV. (**) indicates p < 0.001 (one way ANOVA) with respect to the
Ctrl. (B) Higher concentrations of DCQ (5 and 10 μM) induced increases in the PreG1 phase population more so under hypoxia. Treatment with
DCQ in normoxia or hypoxia was for 6 hrs, after which cells were harvested immediately and DNA was stained with PI for analysis with FACScan
flow cytometry. The percentage of Pre G1 cells was calculated using Cell Quest. (C) Annexin V assay showing the apoptotic/necrotic response of
p53
+/+ cells exposed to 5 or 10 μM DCQ for 6 hr in normoxia or hypoxia. Apoptosis was assayed 24 hr after drug treatment, and appeared to be
enhanced in hypoxia at higher drug concentrations. Quadrant A = apoptotic cells, B = apoptotic+necrotic, C = normal, D = necrotic. The
experiment was repeated twice each in duplicates.
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case of p21 increase) or apoptosis [29,30]. In addition,
ATM can lead to the activation of PIDD, an important
target gene in a signaling pathway that is initiated by
p53, subsequently causing either activation of NFB-
dependent cell survival through PIDD-C or apoptosis
through PIDD-CC [31,32]. To assess the effect of DCQ
on downstream targets of ATM, we investigated its abil-
ity to induce changes in the expression levels of p53,
p21, PIDD-C and caspase-2 proteins. Cells were exposed
to 5 or 10 μM DCQ and protein changes were moni-
tored 6 hrs post-treatment under normoxia or hypoxia.
The p53 protein increased in response to DCQ in all
three cell lines except in p53
+/+ cells exposed to hypoxia
(Figure 6A); p21 protein also increased in all cell lines
except in p53
+/+ cells exposed to normoxia (Figure 6A).
Exposure of the p53
+/+ cells to 5 or 10 μM DCQ gradu-
ally increased the level of caspase-2, and the upregula-
tion was 8-10 fold higher under hypoxia (Figure 6C). In
p21
-/- cells, DCQ treatment under normoxia increased
Figure 4 DCQ is not cytotoxic to normal intestinal cells. DCQ at concentrations of up to 10 μM did not reduce FHs74 Int human normal
intestinal cell viability. At 50% confluency, cells were exposed to DCQ for 6 hr or were left untreated. Viability was assessed by the Cytotox 96
non-radioactive assay (A) and by the MTT-based Promega assay (B). Values are averages ± SE of two independent experiments each done in
triplicates. The experiment was repeated three times each in triplicates.
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Page 8 of 13caspase-2 expression levels. The exposure of p21
-/- cells
to hypoxia alone increased caspase-2 expression, how-
ever the combination of DCQ and hypoxia reduced it
(Figure 6C). DCQ had no effect on caspase-2 protein
expression in p53
-/- cells which is not surprising, since
p53 is known to regulate caspase-2 [33]. Although no
direct interaction between p53 and caspase-2 has been
observed, it is believed that a functional connection
between these two proteins is essential for the initiation
of drug-induced apoptosis [34]. Enforced PIDD expres-
sion or the over expression of p53 have been shown to
promote cell death through the activation of caspase-2
[33,34]. In p53
+/+ and p53
-/- cells, DCQ downregulated
PIDD-C protein expression under normoxia and




The low oxygen tension in solid tumors is one major
factor for tumor resistance to radiotherapy and che-
motherapy; therefore there is interest in the discovery of
novel drugs that can specifically target tumor cells. In
this study, we showed that DCQ is a DNA damaging
and apoptotic agent that reduces the viability and colony
forming ability of colon cancer cells and is non-toxic to
normal intestinal cells. We have shown previously that
DCQ is not toxic to normal mouse intestinal Mode K
and IEC-6 cells [9] or to normal mouse mammary SCP2
Figure 5 DCQ induces DNA damage and increases ATM expression in p53
+/+ HCT116 cells. SSB and DSB induced by DCQ in p53
+/+ cell
line. (A) Examples of comets induced by DCQ in cells subjected to the alkaline comet assay. Cells treated with DCQ for 6 hrs in normoxia or
hypoxia were collected directly after treatment, subjected to the alkaline comet assay and images were taken using a fluorescent microscope at
40× (oil immersion) magnification. The comets observed by each treatment are directly proportional to the amount of SSBs induced. (B) The
mean of the parameters (% DNA in comet’ s tail and tail moment) are shown in the graphs above. More than 50 cells per treatment were
photographed and quantified using TriTek CometScore software. (*) indicates p < 0.05 (one way ANOVA) with respect to control. (C) DCQ-
induced phosphorylation of ATM in p53
+/+ cells at 6 hrs as an indication of DSB. After treatment, cells were fixed and subjected to
immunocytochemical detection of ATM phosphorylated on Ser-1981, and stained with PI to detect at the same time p-ATM in each phase of
the cell cycle. The mean of the FL-1 intensity ± SD (reflecting the level of p-ATM expression) at the G1, S and G2M phases of the cell cycle are
shown in the table. The experiment was repeated twice each in duplicates.
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Page 9 of 13cells [unpublished findings], suggesting the selectivity of
this drug to cancer cells.
The reduction of viability and colony survival by DCQ
was more pronounced under hypoxia than normoxia and
was evident in all HCT116 cell lines, particularly in p21
-/-
cells which showed greater drug-induced increases in
Pre-G1. The apoptotic effects of DCQ in p53
+/+ cells cor-
related with an increase in the pro-apoptotic caspase-2
protein, inhibition of the pro-survival protein PIDD-C,
and increase in p-ATM expression, a major protein
kinase involved in repair of DSB.
DCQ belongs to a group of heterocyclic compounds
with potent hypoxic cytotoxic activities [4], of which the
heterocyclic di-N-oxide TPZ is in phase III clinical trials
[35]. The hypoxia toxicity of TPZ is due to the produc-
tion of radicals that form strand breaks in the DNA
[35,36]. Under normoxic conditions, the radical is back-
oxidized to the nontoxic original compound with the
related production of the much less toxic superoxide
radical [36]. Unlike TPZ which is active only under
hypoxia, DCQ appears to be equally active in HCT116
cells cultured in both normoxic and hypoxic environ-
ments which explains the low HCR ratios of (< 1.5) spe-
cific for this cell line. This is in contrast to the high
HCR ratios (> 100) in T-84 human colon cancer cells
[4], suggesting that the hypoxia potency of DCQ is cell-
type specific.
Hypoxia-Inducible Factor-1alpha (HIF-1a)i sa n
important cellular transcription factor that is stabilized
under hypoxia [reviewed in [37]]. HIF-1a regulates the
metabolic adaptation to O2 d e p r i v a t i o ni nt u m o r s ,a n d
p l a y sa ne s s e n t i a lr o l ei na l l o w i n gt u m o r st oe s c a p e
Figure 6 DCQ modulates the protein expression levels of key mediators of apoptosis and mitotic catastrophe. At 50% confluency, cells
were treated with 5 or 10 μM DCQ for 6 hrs. Whole cell lysates were then immunoblotted with the different primary antibodies and probed
with GAPDH to ensure equal loading. (A) p53 and p21 protein expression and (B) caspase-2 and PIDD-C protein expression in HCT116 cell lines
in response to DCQ treatment under normoxic or hypoxic conditions. (C) Relative densitometry values of analyzed proteins are plotted. All
values were normalized to GAPDH and calculated relative to the control cells cultured under normoxia. The experiment was repeated twice each
in duplicates.
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DCQ has previously been shown to decrease HIF-1a
mRNA and protein expression levels in mouse mam-
mary carcinoma cell lines [8]. Here we show that DCQ
decreased HIF-1a p r o t e i ne x p r e s s i o ni np 5 3
+/+ and
p53
-/- HCT116 cell lines, despite the constitutive expres-
sion of HIF-1a under both normoxic and hypoxic con-
ditions in the latter cell line (Figure 3B). This result is
interesting in light of the literature showing that hypoxia
selects for p53 mutant tumors [26]. Furthermore, inter-
fering with HIF-1a is important for effective antitumor
therapy [37].
Mitotic catastrophe occurs during, or shortly after,
dysregulated or failed mitosis, and is believed to be fun-
damentally different from apoptosis. Despite its distinc-
tive morphology, mitotic catastrophe may represent a
pre-stage of apoptosis [17]. Apoptosis, however, is not
always required for the lethal effect of mitotic cata-
strophe, since abnormal mitosis can lead to cell death
through apoptosis and necrosis based on the molecular
profile of cells [17]. In our system, we show that at low
doses of DCQ (2.5 μM), the three HCT116 cell lines
displayed an entirely different nuclear morphology with
enlarged nuclei, a morphology that has been previously
k n o w nt or e s u l tf r o mm i t o t i cc a t a s t r o p h e( F i g u r e3 A ) .
No signs of mitotic catastrophe were observed at higher
DCQ concentrations of 5 or 10 μMo ra ts h o r t e ri n c u -
bation times (data not shown). Rather high drug con-
centrations induced a significant increase in Pre-G1,a
sign apoptosis and necrosis (Figure 3B).
Having determined that DCQ induces mitotic cata-
strophe at lower drug concentrations and apoptosis at
higher concentrations, we next investigated whether it
causes DNA damage and activates ATM in the p53
+/+
cell line. DNA damage imposes a threat to the survival
of cells if the damage is unrepaired [12]. As a response
to the damage, cells activate the DNA damage check-
point. DSBs are detected by two main players in the
DNA damage checkpoint: ATM and DNA-PK. Signal
transduction, induced by the activation of ATM, can
cause cell-cycle arrest, repair, and cell death. ATM plays
ac r i t i c a lr o l ei nSa n dG 2-M phase arrest. Activated by
DSBs, ATM becomes phosph o r y l a t e da tS e r - 1 9 8 1
[30,39]. Our experiments using the alkaline comet assay
show that DCQ causes SSB and DSB in p53
+/+ cells
under normoxic and hypoxic conditions, however, the
extent of DNA strand breaks was higher under hypoxia.
Interestingly, ATM was activated in all phases of the
cell cycle in response to the DNA damage induced by
DCQ especially under hypoxia (Figure 5), suggesting a
positive correlation between the extent of DNA damage
and the activation of ATM.
The p21 gene is transcriptionally activated by p53 and
is responsible for the p53-dependent checkpoint which
induces cell cycle arrest after DNA damage. Enforced
p21 expression is known to result in a consistent, but
partial, protection of cells from apoptosis [40,41]. In
HCT116, a significant increase was observed in p21
expression in response to DCQ treatment under hypoxia
both in p53
+/+ and p53
-/- cells suggesting that p21 acti-
vation is independent of p53. In addition, the decrease
in the expression levels of the prosurvival PIDD-C pro-
tein coupled with the increase in proapoptotic caspase-2
in p53
+/+ cells, appears to have committed the cells to
apoptosis. In p53
-/- and p21
-/- HCT116, the apoptotic
cell death occurred independent of caspase-2 activation
and/or PIDD-C downregulation (Figure 6B), suggesting
the involvement of other mediators of apoptosis.
It has been debated if mitotic catastrophe results in
cell death via caspase2-dependent or - independent
mechanisms [42]. At least three lines of evidence indi-
cate that, in our cell system, mitotic catastrophe is inde-
pendent of p53 and/or caspase-2 activation. First,
mitotic catastrophe occurred in drug treated cells that
are null for p53 (Figure 3A). Second, in p53
+/+ cells,
higher doses of 5 and 10 μM DCQ induced caspase-2
activation (Figure 6B), while morphological changes of
mitotic catastrophe were observed at lower drug doses
(Figure 3A). Third, the three HCT116 cell lines dis-
played signs of mitotic catastrophe, yet only p53
+/+ cells
showed activation of caspase-2, and especially under
hypoxia (Figure 6B). Although, it was suggested that the
presence of functional p53 in cancer cells enhanced
their sensitivity to hypoxia, DCQ-induced apoptosis in
HCT116 was not dependent on the presence of the p53
gene, as the Pre-G1 increase was evident even in cells
lacking the p53 gene (Figure 3B).
Conclusions
DCQ is a selective cytotoxin in HCT116 human colon
cancer cells and its toxicity is independent of p53 and
p21. DCQ toxicity is associated with enhanced DNA
damage, activation of the ATM damage repair pathway,
as well as induction of apoptosis or mitotic catastrophe
depending on the drug concentration used. The absence
of major toxicity to normal cell lines (human intestinal
cells in this study and mouse intestinal cells and mouse
mammary cells in previous studies) makes DCQ an
interesting compound with potential anticancer activities
against colon cancer, and therefore a drug for further
testing.
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